The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

3D Cell Culture Market by Scaffold Format (Scaffold Based / Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Microfluidic System, Microcarrier, Organ-on-Chip and Others), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions: Industry Trends and Global Forecasts (3rd Edition), 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    October 2020

  • Pages
    516

  • View Count
    2026

Example Insights

3D-Cell-Culture-Market-Context 3D-Cell-Culture-Market-Papular-Keywords 3D-Cell-Culture-Market-List-Of-Products 3D-Cell-Culture-Market-Distribution-by-Leading-Players
3D-Cell-Culture-Market-3D-Bioreactors 3D-Cell-Culture-Market-Papular-Areas-Of-Applications 3D-Cell-Culture-Market-Distribution-by-Location 3D-Cell-Culture-Market-Partnerships-and-Callaborations
3D-Cell-Culture-Market-Patent-Analysis 3D-Cell-Culture-Market-Market-Forcast 3D-Cell-Culture-Market-Distribution-by-Geography  

 

Overview

Animal cell cultures represent an integral part of the drug discovery and development process. The conventional 2 dimensional (2D) cell culturing format is still extensively used in early stage research and is instrumental in establishing initial proof-of-concept and validating mechanisms of action of pharmacological leads. However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.  

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research. This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases. Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

Scope of the Report

The “3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030” report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:

  • An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
  • A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence.
  • A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence.
  • A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence.
  • An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used. 
  • Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook.
  • An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products. 
  • An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
  • An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis. 
  • An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. 
  • An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
  • Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players: 

  • Brigitte Angres (Co-founder, Cellendes)
  • Bill Anderson (President and CEO, Synthecon)
  • Anonymous (President and CEO, Anonymous)
  • Anonymous (Co-founder and Vice President, Anonymous)
  • Scott Brush (Vice President, BRTI Life Sciences)
  • Malcolm Wilkinson (Managing Director, Kirkstall)
  • Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
  • Tanya Yankelevich (Director, Xylyx Bio)
  • Jens Kelm (Chief Scientific Officer, InSphero)
  • Walter Tinganelli (Group Leader, GSI)
  • Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players engaged in the development of 3D cell culture products?
  • What are the most popular 3D cell culture products?
  • What are the different applications for which 3D cell culture products are currently being developed?
  • What are the key factors that are likely to influence the evolution of this market?
  • What is the trend of capital investments in the 3D cell culture systems market?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • How is the COVID-19 pandemic likely to impact the 3D cell culture systems market?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to 3D cell culture systems market?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term. 

Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used. 

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis. 

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions)
Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.

Tables Of Contents

 1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1. Chapter Overview
3.2. Types of Cell Cultures
3.2.1. Primary Cell Cultures
3.2.2. Cell Lines

3.3. Morphology of Cells in Culture
3.4. Transition from 2D to 3D Cell Cultures

3.5. Overview of 3D Cell Culturing
3.5.1. Components of the Extracellular Matrix (ECM)
3.5.2. In Vitro Cell Culturing
3.5.3. Selection of Culture Format

3.6. Establishment and Maintenance of Cell Cultures
3.6.1. Isolating Cells from Tissues
3.6.2. Maintaining Cells in Culture
3.6.3. Sub-Culturing / Passaging 
3.6.4. Cryogenic Storage

3.7. Requirements for Maintaining the Health of Cell Cultures
3.7.1. Safety Guidelines in a Cell Culture Facility
3.7.2. Cell Culture Health and Optimal Conditions for Growth
3.7.3. Concerns Related to Cross Contamination
3.7.4. Methods to Prevent Contamination

3.8. Need for 3D Cell Culture Systems
3.8.1. Model Systems
3.8.2. Drug Discovery and Preclinical Research
3.8.3. Cancer Research
3.8.4. Virology Research
3.8.5. Genetic Engineering and Gene Therapy Research

3.9. Advantages and Limitations of 3D Cell Culture Systems
3.10. Future Perspectives

4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS 
4.1. 3D Cell Culture Classification
4.2. Scaffold based 3D Cell Cultures
4.2.1. Hydrogels / ECM Analogs
4.2.2. Solid Scaffolds
4.2.3. Micropatterned Surfaces
4.2.4. Microcarriers

4.3. Scaffold Free 3D Cell Cultures
4.3.1. Attachment Resistant Surfaces
4.3.2. Suspension Culture Systems
4.3.2.1. Hanging Drop Plates
4.3.2.2. Magnetic Levitation and 3D Bioprinting
4.3.3. Microfluidic Surfaces and Organs-on-Chips
4.3.4. 3D Bioreactors

4.4. Organoids

5. FABRICATION OF 3D MATRICES AND SCAFFOLDS
5.1. Chapter Overview
5.2. Methods for Fabricating Porous Scaffolds
5.2.1. Particulate Leaching
5.2.2. Solvent Casting
5.2.3. Emulsion Templating
5.2.4. Gas Foaming
5.2.5. Melt Molding
5.2.6. Microsphere Sintering

5.3. Methods for Fabricating Fibrous Scaffolds
5.3.1. Electrospinning
5.3.2. Phase Separation
5.3.3. Self-Assembly
5.3.4. Fiber Mesh and Fiber Bonding

5.4. Methods for Fabricating Hydrogels
5.4.1. Gelation
5.4.2. Solvent Casting and Particulate Leaching
5.4.3. Gas Foaming
5.4.4. Freeze Drying
5.4.5. Co-polymerization / Crosslinking Methods
5.4.6. Microfluidics

5.5. Methods for Fabricating Custom Scaffolds
5.5.1. Stereo-Lithography
5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
5.5.3. Fused Deposition Modeling
5.5.4. Membrane Lamination
5.5.5. Rapid Prototyping / Solid Free-Form Technique

5.6. Methods for Fabricating Microspheres
5.6.1. Solvent Evaporation
5.6.2. Single and Double Emulsification
5.6.3. Particle Aggregation

5.7. Methods for Fabricating Native Scaffolds
5.7.1. Decellularization

6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE
6.1. Chapter Overview
6.2. 3D Cell Culture System Developers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by 3D Cell Culture Format 
6.2.5. Analysis by Type of Product

6.3. Heat Map Representation: Analysis by 3D Cell Culture Format and Location of Headquarters
6.4. Tree Map Representation: Analysis by Company Size and Type of Product
6.5. World Map Representation: Analysis by Location of Regional Headquarters

6.6. 3D Cell Cultures: List of Service Providers
6.7. 3D Cell Cultures: List of Assays, Kits and Reagents

7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS
7.1. Chapter Overview
7.2. Scaffold based Products: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Source of 3D Cultured Cells
7.2.4. Analysis by Method Used for Fabrication
7.2.5. Analysis by Material Used for Fabrication
7.2.6. Analysis by Type of Product and Source of 3D Cultured Cells 
7.2.7. Analysis by Type of Product and Method Used for Fabrication

7.3. Scaffold Based Products: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters

7.4. Leading Developers: Analysis by Number of Scaffold based Products
7.5. Tree Map Representation: Analysis by Type of Product and Company Size

8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS
8.1. Chapter Overview
8.2. Scaffold Free Products: Overall Market Landscape
8.2.1. Analysis by Status of Development
8.2.2. Analysis by Type of Product
8.2.3. Analysis by Source of 3D Cultured Cells
8.2.4. Analysis by Method Used for Fabrication
8.2.5. Analysis by Material Used for Fabrication
8.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
8.2.7. Analysis by Type of Product and Method Used for Fabrication

8.3. Scaffold Free Products: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters

8.4. Leading Developers: Analysis by Number of Scaffold Free Products
8.5. Tree Map Representation: Analysis by Type of Product and Company Size

9. MARKET LANDSCAPE: 3D BIOREACTORS
9.1. Chapter Overview
9.2. 3D Bioreactors: Overall Market Landscape
9.2.1. Analysis by Type of 3D Bioreactor
9.2.2. Analysis by Working Volume

9.3. 3D Bioreactors: Developer Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters

9.4. Leading Developers: Analysis by Number of 3D Bioreactors

10. KEY APPLICATION AREAS 
10.1. Chapter Overview
10.2. 3D Cell Culture Systems in Cancer Research
10.2.1. Need for 3D Culture Systems in Cancer Research
10.2.1.1. Improving Cancer Drug Screening with 3D Culture Systems

10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
10.3.1. Drug Development Studies
10.3.2. Toxicity Screening
10.3.2.1. 3D Liver Models
10.3.2.2. Other 3D Models

10.4. 3D Cell Culture Systems in Stem Cell Research
10.4.1. Potential of 3D Culture Systems in Stem Cell Differentiation
10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation

10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering

10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
10.6.1.1. Scaffold based 3D Products: Analysis by Key Application Areas
10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas

11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)
11.1. Chapter Overview
11.1.1. 3D Biotek
11.1.1.1. Company Overview
11.1.1.2. Product Portfolio
11.1.1.3. Recent Developments and Future Outlook

11.1.2. Advanced BioMatrix
11.1.2.1. Company Overview
11.1.2.2. Product Portfolio
11.1.2.3. Recent Development and Future Outlook

11.1.3. Alphabioregen
11.1.3.1. Company Overview
11.1.3.2. Product Portfolio
11.1.3.3. Recent Developments and Future Outlook

11.1.4. Corning Life Sciences
11.1.4.1. Company Overview
11.1.4.2. Product Portfolio
11.1.4.3. Recent Developments and Future Outlook

11.1.5. REPROCELL
11.1.5.1. Company Overview
11.1.5.2. Product Portfolio
11.1.5.3. Recent Developments and Future Outlook

12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIP DEVELOPERS)
12.1. Chapter Overview
12.1.1. CN Bio Innovations
12.1.1.1. Company Overview
12.1.1.2. Financial Information
12.1.1.3. Product Portfolio
12.1.1.4. Recent Developments and Future Outlook

12.1.2. Emulate
12.1.2.1. Company Overview
12.1.2.2. Financial Information
12.1.2.3. Product Portfolio
12.1.2.4. Recent Developments and Future Outlook

12.1.3. InSphero
12.1.3.1. Company Overview
12.1.3.2. Financial Information
12.1.3.3. Product Portfolio
12.1.3.4. Recent Developments and Future Outlook
12.1.4. Mimetas
12.1.4.1. Company Overview
12.1.4.2. Financial Information
12.1.4.3. Product Portfolio
12.1.4.4. Recent Developments and Future Outlook

12.1.5. TissUse
12.1.5.1. Company Overview
12.1.5.2. Product Portfolio
12.1.5.3. Recent Developments and Future Outlook

13. COMPANY PROFILES: 3D BIOREACTORS
13.1. Chapter Overview
13.2. BISS TGT
13.2.1. Company Overview
13.2.2. Product Portfolio
13.2.3. Recent Developments and Future Outlook

13.3. Celartia
13.3.1. Company Overview
13.3.2. Product Portfolio
13.3.3. Recent Developments and Future Outlook

13.4. Cell Culture
13.4.1. Company Overview
13.4.2. Product Portfolio
13.4.3. Recent Developments and Future Outlook

13.5. Cesco Bioengineering
13.5.1. Company Overview
13.5.2. Product Portfolio
13.5.3. Recent Developments and Future Outlook

13.6. Flexcell International
13.6.1. Company Overview
13.6.2. Product Portfolio
13.6.3. Recent Developments and Future Outlook

13.7. PBS Biotech
13.7.1. Company Overview
13.7.2. Product Portfolio
13.7.3. Recent Developments and Future Outlook

13.8. Synthecon
13.8.1. Company Overview
13.8.2. Product Portfolio
13.8.3. Recent Developments and Future Outlook

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. 3D Cell Culture Systems: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by 3D Cell Culture Format
14.3.5. Analysis by Type of Product
14.3.6. Analysis by Geography 
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Amount of Funding
14.3.9. Most Active Investors: Analysis by Number of Instances
14.4 Concluding Remarks

15. PARTNERSHIPS AND COLLABORATIONS 
15.1. Chapter Overview
15.2. Partnership Models
15.3. 3D Cell Culture Systems: Recent Partnerships and Collaborations 
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.2.1. Analysis by Year of Partnership and Type of Partnership
15.3.2.2. Analysis by Company Size and Type of Partnership

15.3.3. Analysis by Type of Partner
15.3.3.1. Analysis by Year of Partnership and Type of Partner
15.3.3.2. Analysis by Type of Partnership and Type of Partner

15.3.4. Analysis by 3D Cell Culture Format
15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format

15.3.5. Analysis by Type of Product
15.3.5.1. Analysis by Year of Partnership and Type of Product
15.3.5.2. Analysis by Type of Partnership and Type of Product

15.3.6. Most Active Players: Analysis by Number of Partnerships
15.3.7. Regional Analysis
15.3.8. Intercontinental and Intracontinental Agreements

16. PATENT ANALYSIS 
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. 3D Cell Culture Systems: Patent Analysis
16.3.1. Analysis by Type of Patent
16.3.2. Analysis by Publication Year
16.3.3. Analysis by Issuing Authority
16.3.4. Analysis by CPC Symbols
16.3.5. Emerging Focus Area
16.3.6. Leading Players: Analysis by Number of Patents

16.4. 3D Cell Culture Systems: Patent Valuation Analysis
16.5. Leading Patents: Analysis by Number of Citations

17. MARKET FORECAST
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Impact of COVID-19 Pandemic on Global 3D Cell Culture Market
17.4. Global 3D Cell Culture Market, 2020-2030

17.5. Global 3D Cell Culture Market: Distribution by Business Segment
17.5.1. 3D Cell Culture Systems Market, 2020-2030
17.5.2. 3D Cell Culture Consumables Market, 2020-2030
17.5.3. 3D Cell Culture Services Market, 2020-2030

17.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
17.6.1. 3D Cell Culture Systems Market for Scaffold based Products, 2020-2030
17.6.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2020-2030
17.6.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2020-2030

17.7. Global 3D Cell Culture Systems Market: Distribution by Type of Product
17.7.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2020-2030
17.7.2. 3D Cell Culture Systems Market for Hydrogels / ECMs, 2020-2030
17.7.3 3D Cell Culture Systems Market for Micropatterned Surface, 2020-2030
17.7.4. 3D Cell Culture Systems Market for Microcarriers, 2020-2030
17.7.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2020-2030
17.7.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2020-2030
17.7.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2020-2030

17.8. Global 3D Cell Culture Systems Market: Distribution by Area of Application
17.8.1. 3D Cell Culture Systems Market for Cancer Research, 2020-2030
17.8.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2020-2030
17.8.3. 3D Cell Culture Systems Market for Stem Cell Research, 2020-2030
17.8.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2020-2030

17.9. Global 3D Cell Culture Systems Market: Distribution by Purpose
17.9.1. 3D Cell Culture Systems Market for Research Use, 2020-2030
17.9.2 3D Cell Culture Systems Market for Therapeutic Use, 2020-2030

17.10. Global 3D Cell Culture Systems Market: Distribution by Geography
17.10.1. 3D Cell Culture Systems Market in North America, 2020-2030
17.10.2 3D Cell Culture Systems Market in Europe, 2020-2030
17.10.3. 3D Cell Culture Systems Market in Asia-Pacific, 2020-2030
17.10.4. 3D Cell Culture Systems Market in Latin America, 2020-2030
17.10.4. 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2020-2030
17.10.5. 3D Cell Culture Systems Market in Rest of the World, 2020-2030

17.11. Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020

17.12. Concluding Remarks

18. SURVEY ANALYSIS
18.1. Chapter Overview
18.2. Overview of Respondents
18.2.1. Designation of Respondents

18.3. Survey Insights
18.3.1. 3D Cell Culture Format
18.3.2. Type of Product(s) Offered
18.3.3. Status of Development of Product(s)
18.3.4. Source of 3D Cultured Cells
18.3.5. Method Used for Fabrication
18.3.6. Area(s) of Application
18.3.7. Services Offered for 3D Cell Cultures
18.3.8. Current and Future Market Opportunity

19. CONCLUSION

20. EXECUTIVE INSIGHTS
20.1. Chapter Overview

20.2. Cellendes 
20.2.1. Company Snapshot
20.2.2. Interview Transcript: Brigitte Angres, Co-founder

20.3. Synthecon 
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Bill Anderson, President and CEO

20.4. Anonymous 
20.4.1. Interview Transcript: Anonymous, President and CEO

20.5. Anonymous 
20.5.1. Interview Transcript: Anonymous, Co-founder and Vice President

20.6. BRTI Life Sciences 
20.6.1. Company Snapshot
20.6.2. Interview Transcript: Scott Brush, Vice President

20.7. Kirkstall
20.7.1. Company Snapshot
20.7.2. Interview Transcript: Malcolm Wilkinson, Managing Director

20.8. QGel
20.8.1. Company Snapshot
20.8.2. Interview Transcript: Ryder Clifford, Director and Simone Carlo Rizzi, Chief Scientific Officer

20.9. Xylyx Bio
20.9.1. Company Snapshot
20.9.2. Interview Transcript: Tanya Yankelevich, Director

20.10. InSphero 
20.10.1. Company Snapshot
20.10.2. Interview Transcript: Jens Kelm, Chief Scientific Officer

20.11. GSI
20.11.1. Company Snapshot
20.11.2. Interview Transcript: Walter Tinganelli, Group Leader

20.12. Nanofiber Solutions 
20.12.1. Company Snapshot
20.12.2. Interview Transcript: Darlene Thieken, Project Manager

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Classification of Cell Cultures
Figure 3.2 Types of 2D and 3D Cell Culture Systems
Figure 3.3 Key Components of ECM
Figure 3.4 Factors Influencing the Selection of 3D Cell Culture Systems
Figure 3.5 Methods Used for Isolation of Cells from Tissues
Figure 3.6 Methods Used for Cryogenic Storage
Figure 3.7 Required Biosafety Levels for Cell Cultures
Figure 3.8 Key Applications of Cell Cultures
Figure 3.9 Shapes of 3D Spheroids Generated via 3D Cell Culture Systems
Figure 3.10 Advantages and Limitations of 3D Cell Culture Systems
Figure 4.1 Classification of 3D Cell Culture Systems
Figure 4.2 Natural Components of ECM Used for Fabrication of Scaffolds
Figure 4.3 Advantages and Disadvantages of Hydrogels
Figure 4.4 Advantages of Microcarriers
Figure 4.5 Techniques Used for Formation of 3D Spheroids
Figure 4.6 Structures of Spinner Flask and Rotating Wall Bioreactors
Figure 6.1 3D Cell Culture System Developers: Distribution by Year of Establishment
Figure 6.2 3D Cell Culture System Developers: Distribution by Company Size
Figure 6.3 3D Cell Culture System Developers: Distribution by Location of Headquarters
Figure 6.4 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
Figure 6.5 3D Cell Culture System Developers: Distribution by Type of Product
Figure 6.6 3D Cell Culture System Developers: Distribution by Number of 3D Cell Culture Products
Figure 6.7 Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
Figure 6.8 Tree Map Representation: Distribution by Company Size and Type of Product
Figure 6.9 World Map Representation: Distribution by Location of Regional Headquarters
Figure 7.1 Scaffold Based Products: Distribution by Status of Development
Figure 7.2 Scaffold Based Products: Distribution by Type of Product
Figure 7.3 Scaffold Based Products: Distribution by Source of 3D Cultured Cells
Figure 7.4 Scaffold Based Products: Distribution by Method Used for Fabrication
Figure 7.5 Scaffold Based Products: Distribution by Material Used for Fabrication
Figure 7.6 Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
Figure 7.7 Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
Figure 7.8 Scaffold Based Product Developers: Distribution by Year of Establishment
Figure 7.9 Scaffold Based Product Developers: Distribution by Company Size
Figure 7.10 Scaffold Based Product Developers: Distribution by Location of Headquarters
Figure 7.11 Leading Developers: Distribution by Number of Scaffold Based Products
Figure 7.12 Tree Map Representation: Distribution by Type of Product and Company Size
Figure 8.1 Scaffold Free Products: Distribution by Status of Development
Figure 8.2 Scaffold Free Products: Distribution by Type of Product
Figure 8.3 Scaffold Free Products: Distribution by Source of 3D Cultured Cells
Figure 8.4 Scaffold Free Products: Distribution by Method Used for Fabrication
Figure 8.5 Scaffold Free Products: Distribution by Material Used for Fabrication
Figure 8.6 Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
Figure 8.7 Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
Figure 8.8 Scaffold Free Product Developers: Distribution by Year of Establishment
Figure 8.9 Scaffold Free Product Developers: Distribution by Company Size
Figure 8.10 Scaffold Free Product Developers: Distribution by Location of Headquarters
Figure 8.11 Leading Developers: Distribution by Number of Scaffold Free Products
Figure 8.12 Tree Map Representation: Distribution by Type of Product and Company Size
Figure 9.1 3D Bioreactors: Distribution by Type of 3D Bioreactor
Figure 9.2 3D Bioreactors: Distribution by Working Volume
Figure 9.3 3D Bioreactor Developers: Distribution by Year of Establishment
Figure 9.4 3D Bioreactor Developers: Distribution by Company Size
Figure 9.5 3D Bioreactor Developers: Distribution by Location of Headquarters
Figure 9.6 Leading Developers: Distribution by Number of 3D Bioreactors
Figure 10.1 Key Application Areas of 3D Cell Culture Systems
Figure 10.2 3D Cell Culture Systems in Cancer Research
Figure 10.3 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
Figure 10.4 Methods Used for Embryoid Body Formation
Figure 10.5 Top-Down and Bottom-Up Approaches for Tissue Engineering
Figure 10.6 3D Cell Culture Systems: Distribution by Key Application Areas
Figure 10.7 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
Figure 10.8 Scaffold Based 3D Products: Distribution by Key Application Areas
Figure 10.9 Scaffold Free 3D Products: Distribution by Key Application Areas
Figure 10.10 3D Bioreactors: Distribution by Key Application Areas
Figure 13.1 Key Features of 3D Perfusion Bioreactors
Figure 13.2 MagDrive and AirDrive Mechanisms for PBS Bioreactors
Figure 13.3 Advantages of Rotary Cell Culture System (RCCS)
Figure 14.1 Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015-Q3 2020
Figure 14.2 Funding and Investments: Cumulative Number of Funding Instances by Year, 2015 – Q3 2020
Figure 14.3 Funding and Investments: Cumulative Amount Invested, 2015 – Q3 2020 (USD Million)
Figure 14.4 Funding and Investments: Distribution of Instances by Type of Funding, 2015 – Q3 2020
Figure 14.5 Funding and Investments: Year-Wise Distribution of Instances and Type of Funding, 2015 – Q3 2020
Figure 14.6 Funding and Investments: Distribution by Amount Invested and Type of Funding, 2015 – Q3 2020 (USD Million)
Figure 14.7 Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 – Q3 2020
Figure 14.8 Funding and Investments: Distribution by Number of Instances and Amount Invested by 3D Cell Culture Format, 2015 – Q3 2020
Figure 14.9 Funding and Investments: Distribution by Number of Instances and Amount Invested by Type of Product, 2015 – Q3 2020
Figure 14.10 Funding and Investments: Distribution by Geography
Figure 14.11 Funding and Investments: Regional Distribution by Total Amount Invested, 2015 – Q3 2020
Figure 14.12 Most Active Players: Distribution by Number of Funding Instances, 2015 – Q3 2020
Figure 14.13 Most Active Players: Distribution by Amount Raised, 2015 – Q3 2020 (USD Million)
Figure 14.14 Most Active Investors: Distribution by Number of Funding Instances, 2015–Q3 2020
Figure 14.15 Funding and Investment Summary, 2015 – Q3 2020 (USD Million)
Figure 15.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015 - Q3 2020
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Figure 15.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 15.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 15.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 15.8 Partnerships and Collaborations: Distribution by 3D Cell Culture Format
Figure 15.9 Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
Figure 15.10 Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
Figure 15.11 Partnerships and Collaborations: Distribution by Type of Product
Figure 15.12 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 15.13 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 15.14 Most Active Players: Distribution by Number of Partnerships
Figure 15.15 Partnerships and Collaborations: Regional Distribution
Figure 15.16 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 16.1 Patent Analysis: Distribution by Type of Patent
Figure 16.2 Patent Analysis: Cumulative Distribution by Publication Year, 2015 - Q3 2020
Figure 16.3 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015 - Q3 2020
Figure 16.4 Patent Analysis: Distribution of Filed Patents Publication Year, 2015 - Q3 2020
Figure 16.5 Patent Analysis: Distribution by Patent Type and Publication Year, 2015 - Q3 2020
Figure 16.6 Patent Analysis: Distribution by Issuing Authority
Figure 16.7 Patent Analysis: Distribution by CPC Symbols
Figure 16.8 Patent Analysis: Distribution by Emerging Focus Area
Figure 16.9 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2015 - Q3 2020
Figure 16.10 Leading Patent Assignees (Industry Players): Distribution by Number of Patents
Figure 16.11 Leading Patent Assignees (Non-Industry Players): Distribution by Number of Patents
Figure 16.12 Patent Analysis: Distribution by Patent Age, 2000-2020
Figure 16.13 Patent Analysis: Distribution by Proprietary Scoring Criteria
Figure 16.14 Patent Analysis: Valuation Analysis
Figure 17.1 Global 3D Cell Culture Market, 2020-2030 (USD Million)
Figure 17.2 Global 3D Cell Culture Market: Distribution by Business Segment, 2020 and 2030
Figure 17.3 3D Cell Culture Systems Market, 2020-2030 (USD Million)
Figure 17.4 3D Cell Culture Consumables Market, 2020-2030 (USD Million)
Figure 17.5 3D Cell Culture Services Market, 2020-2030 (USD Million)
Figure 17.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2020-2030
Figure 17.7 3D Cell Culture Systems Market for Scaffold Based Products, 2020-2030 (USD Million)
Figure 17.8 3D Cell Culture Systems Market for Scaffold Free Products, 2020-2030 (USD Million)
Figure 17.9 3D Cell Culture Systems Market for 3D Bioreactors, 2020-2030 (USD Million)
Figure 17.10 Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2020 and 2030
Figure 17.11 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2020-2030 (USD Million)
Figure 17.12 3D Cell Culture Systems Market for Hydrogels / ECMs, 2020-2030 (USD Million)
Figure 17.13 3D Cell Culture Systems Market for Micropatterned Surface, 2020-2030 (USD Million)
Figure 17.14 3D Cell Culture Systems Market for Microcarriers, 2020-2030 (USD Million)
Figure 17.15 3D Cell Culture Systems Market for Microfluidic Systems, 2020-2030 (USD Million)
Figure 17.16 3D Cell Culture Systems Market for Solid Scaffolds, 2020-2030 (USD Million)
Figure 17.17 3D Cell Culture Systems Market for Suspension Cultures, 2020-2030 (USD Million)
Figure 17.18 Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2020 and 2030
Figure 17.19 3D Cell Culture Systems Market for Cancer Research, 2020-2030 (USD Million)
Figure 17.20 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2020-2030 (USD Million)
Figure 17.21 3D Cell Culture Systems Market for Stem Cell Research, 2020-2030 (USD Million)
Figure 17.22 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2020-2030 (USD Million)
Figure 17.23 Global 3D Cell Culture Systems Market: Distribution by Purpose, 2020-2030
Figure 17.24 3D Cell Culture Systems Market for Research Use, 2020-2030 (USD Million)
Figure 17.25 3D Cell Culture Systems Market for Therapeutic Use, 2020-2030 (USD Million)
Figure 17.26 Global 3D Cell Culture Systems Market: Distribution by Geography, 2020- 2030
Figure 17.27 3D Cell Culture Systems Market in North America, 2020-2030 (USD Million)
Figure 17.28 3D Cell Culture Systems Market in Europe, 2020-2030 (USD Million)
Figure 17.29 3D Cell Culture Systems Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 17.30 3D Cell Culture Systems Market in Latin America, 2020-2030 (USD Million)
Figure 17.31 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2020-2030 (USD Million)
Figure 17.32 3D Cell Culture Systems Market in Rest of the World, 2020-2030 (USD Million)
Figure 17.33 Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
Figure 17.34 Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 18.1 Survey Insights: Distribution of Respondents by Year of Establishment of the Company
Figure 18.2 Survey Insights: Distribution of Respondents by Company Size
Figure 18.3 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
Figure 18.4 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Figure 18.5 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Figure 18.6 Survey Insights: Distribution by Focus Area
Figure 18.7 Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
Figure 18.8 Survey Insights: Distribution by Status of Development of Product(s)
Figure 18.9 Survey Insights: Distribution by Method of Fabrication Used
Figure 18.10 Survey Insights: Distribution by Source of Cultured Cells
Figure 18.11 Survey Insights: Distribution by Key Applications
Figure 18.12 Survey Insights: Distribution by 3D Cell Culture Services Offered
Figure 18.13 Survey Insights: Distribution by Current and Future Market Opportunity, 2020 and 2030
Figure 19.1 3D Cell Culture Systems Market: Concluding Remarks

List Of Tables

Table 3.1 Morphology of Cells in a Culture
Table 3.2 Differences between 2D and 3D Cell Cultures
Table 3.3 Features of 3D Spheroids generated via 3D Cell Culture Systems
Table 4.1 Advantages and Disadvantages of Scaffold Based and Scaffold Free Systems
Table 4.2 Advantages and Disadvantages of Natural and Synthetic Scaffolds
Table 4.3 Advantages and Disadvantages of Natural and Synthetic Hydrogels
Table 4.4 Cell Cultures Used in Magnetic Levitation
Table 4.5 Origin and Culture Techniques Used for Organoids
Table 5.1 Advantages and Disadvantages of Methods Used for Fabrication for Porous Scaffolds
Table 5.2 3D Cell Culture Studies Using Porous Scaffolds
Table 5.3 Methods for Fabrication Used of Fibrous Scaffolds
Table 5.4 Advantages and Disadvantages of Methods Used for Fabrication of Fibrous Scaffolds
Table 5.5 3D Cell Culture Studies Using Fibrous Scaffolds
Table 5.6 Advantages and Disadvantages of Methods Used for Fabrication of Hydrogels
Table 5.7 3D Cell Culture Studies Using Hydrogels
Table 5.8 Advantages and Disadvantages of Methods Used for Fabrication of Custom Scaffolds
Table 5.9 3D Cell Culture Studies Using Custom Scaffolds
Table 5.10 Advantages and Disadvantages of Methods Used for Fabrication of Microspheres
Table 5.11 3D Cell Culture Studies Using Microspheres
Table 5.12 3D Cell Culture Studies Using Native Scaffolds
Table 6.1 3D Cell Culture Systems: List of Developers
Table 6.2 3D Cell Culture Systems: List of Service Providers
Table 6.3 3D Cell Culture Systems: List of Assays, Kits and Reagents
Table 7.1 Scaffold Based Products: List of Products
Table 7.2 Scaffold Based Products: List of Developers
Table 8.1 Scaffold Free Products: List of Products
Table 8.2 Scaffold Free Products: List of Developers
Table 9.1 3D Bioreactors: List of Products
Table 9.2 3D Bioreactors: List of Developers
Table 10.1 Scaffold Based Products: Information on Key Application Areas
Table 10.2 Scaffold Free Products: Information on Key Application Areas
Table 10.3 3D Bioreactors: Information on Key Application Areas
Table 11.1 Scaffold Based Products (Hydrogel / ECM): List of Companies Profiled
Table 11.2 3D Biotek: Company Snapshot
Table 11.3 3D Biotek: Key Characteristics of Hydrogels / ECMs
Table 11.4 Advanced Biomatrix: Company Snapshot
Table 11.5 Advanced Biomatrix: Key Characteristics of Hydrogels / ECMs
Table 11.6 Advanced Biomatrix: Recent Developments and Future Outlook
Table 11.7 Alphabioregen: Company Snapshot
Table 11.8 Alphabioregen: Key Characteristics of Hydrogels / ECMs
Table 11.9 Corning Life Sciences: Company Snapshot
Table 11.10 Corning Life Sciences: Key Characteristics of Hydrogels / ECMs
Table 11.11 Corning Life Sciences: Recent Developments and Future Outlook
Table 11.12 REPROCELL: Company Snapshot
Table 11.13 REPROCELL: Key Characteristics of Hydrogels / ECMs
Table 11.14 REPROCELL: Recent Developments and Future Outlook
Table 12.1 Scaffold Free Products (Organ-on-Chip): List of Companies Profiled
Table 12.2 CN Bio Innovations: Company Snapshot
Table 12.3 CN Bio Innovations: Information on Funding Instances
Table 12.4 CN Bio Innovations: Key Characteristics of Organ-on-Chips Products
Table 12.5 CN Bio Innovations: Recent Developments and Future Outlook
Table 12.6 Emulate: Company Snapshot
Table 12.7 Emulate: Information on Funding Instances
Table 12.8 Emulate: Key Characteristics of Organ-on-Chips Products
Table 12.9 Emulate: Recent Developments and Future Outlook
Table 12.10 InSphero: Company Snapshot
Table 12.11 InSphero: Information on Funding Instances
Table 12.12 InSphero: Key Characteristics of Organ-on-Chips Products
Table 12.13 InSphero: Recent Developments and Future Outlook
Table 12.14 Mimetas: Company Snapshot
Table 12.15 Mimetas: Information on Funding Instances
Table 12.16 Mimetas: Key Characteristics of Organ-on-Chips Products
Table 12.17 Mimetas: Recent Developments and Future Outlook
Table 12.18 Mimetas: Company Snapshot
Table 12.19 Mimetas: Information on Funding Instances
Table 12.20 Mimetas: Key Characteristics of Organ-on-Chips Products
Table 12.21 Mimetas: Recent Developments and Future Outlook
Table 12.22 TissUse: Company Snapshot
Table 12.23 TissUse: Key Characteristics of Organ-on-Chips Products
Table 12.24 TissUse: Recent Developments and Future Outlook
Table 13.1 3D Bioreactors: List of Companies Profiled
Table 13.2 BISS TGT: Company Snapshot
Table 13.3 BISS TGT: Key Characteristics of 3D Bioreactors
Table 13.4 BISS TGT: Recent Developments and Future Outlook
Table 13.5 Celartia: Company Snapshot
Table 13.6 Celartia: Key Characteristics of 3D Bioreactors
Table 13.7 Cell Culture: Company Snapshot
Table 13.8 Cell Culture: Key Characteristics of 3D Bioreactors
Table 13.9 CESCO Bioengineering: Company Snapshot
Table 13.10 CESCO Bioengineering: Key Characteristics of 3D Bioreactors
Table 13.11 EBERS: Company Snapshot
Table 13.12 EBERS: Key Characteristics of 3D Bioreactors
Table 13.13 EBERS: Recent Developments and Future Outlook
Table 13.14 Flexcell International: Company Snapshot
Table 13.15 Flexcell International: Key Characteristics of 3D Bioreactors
Table 13.16 PBS Biotech: Company Snapshot
Table 13.17 PBS Biotech: Key Characteristics of 3D Bioreactors
Table 13.18 Synthecon: Company Snapshot
Table 13.19 Synthecon: Key Characteristics of 3D Bioreactors
Table 14.1 Funding and Investments: Information on Year of Investment, Type of Funding, Amount Raised and Investor, 2015 - Q3 2020
Table 14.2 Funding and Investments: Information on Year of Establishment, Location of Headquarters of Recipients, Focus Area, and Type of Product, 2015 - Q3 2020
Table 15.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership Model, and Partner, 2015 - Q3 2020
Table 15.2 Partnerships and Collaborations: Information on Type of Agreement, Focus Area, and Type of Product, 2015 - Q3 2020
Table 16.1 Patent Analysis: CPC Symbols
Table 16.2 Patent Analysis: Most Popular CPC Symbols
Table 16.3 Patent Analysis: List of Top 10 CPC Symbols
Table 16.4 Patent Analysis: List of Relatively High Value Patents
Table 17.1 Global 3D Cell Culture Systems Market: Key Assumptions Related to Distribution by Type of Products
Table 18.1 Survey Insights: Overview of Respondents
Table 18.2 Survey Insights: Designation and Seniority Level
Table 18.3 Survey Insights: Focus Area of the Company
Table 18.4 Survey Insights: Type of 3D Cell Culture Products Offered
Table 18.5 Survey Insights: Status of Development of Product(s)
Table 18.6 Survey Insights: Method of Fabrication Used
Table 18.7 Survey Insights: Source of 3D Cultured Cells
Table 18.8 Survey Insights: Key Areas of Application
Table 18.9 Survey Insights: 3D Cell Culture Services Offered
Table 18.10 Survey Insights: Current Market Opportunity (2020)
Table 18.11 Survey Insights: Future Market Opportunity (2030)
Table 20.1 Cellendes: Company Snapshot
Table 20.2 Synthecon: Company Snapshot
Table 20.3 BRTI Life Sciences: Company Snapshot
Table 20.4 Kirkstall: Company Snapshot
Table 20.5 QGel: Company Snapshot
Table 20.6 Xylyx Bio: Company Snapshot
Table 20.7 InSphero: Company Snapshot
Table 20.8 GSI: Company Snapshot
Table 20.9 Nanofiber Solutions: Company Snapshot
Table 21.1 3D Cell Culture 7System Developers: Distribution by Year of Establishment
Table 21.2 3D Cell Culture System Developers: Distribution by Company Size
Table 21.3 3D Cell Culture System Developers: Distribution by Location of Headquarters
Table 21.4 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
Table 21.5 3D Cell Culture System Developers: Distribution by Type of Product
Table 21.6 3D Cell Culture System Developers: Distribution by Number of Products
Table 21.7 Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
Table 21.8 Tree Map Representation: Distribution by Company Size and Type of Product
Table 21.9 World Map Representation: Distribution by Location of Regional Headquarters
Table 21.10 Scaffold Based Products: Distribution by Status of Development
Table 21.11 Scaffold Based Products: Distribution by Type of Product
Table 21.12 Scaffold Based Products: Distribution by Source of 3D Cultured Cells
Table 21.13 Scaffold Based Products: Distribution by Method Used for Fabrication
Table 21.14 Scaffold Based Products: Distribution by Material Used for Fabrication
Table 21.15 Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
Table 21.16 Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
Table 21.17 Scaffold Based Product Developers: Distribution by Year of Establishment
Table 21.18 Scaffold Based Product Developers: Distribution by Company Size
Table 21.19 Scaffold Based Product Developers: Distribution by Location of Headquarters
Table 21.20 Leading Developers: Distribution by Number of Scaffold Based Products
Table 21.21 Tree Map Representation: Distribution by Type of Product and Company Size
Table 21.22 Scaffold Free Products: Distribution by Status of Development
Table 21.23 Scaffold Free Products: Distribution by Type of Product
Table 21.24 Scaffold Free Products: Distribution by Source of 3D Cultured Cells
Table 21.25 Scaffold Free Products: Distribution by Method Used for Fabrication
Table 21.26 Scaffold Free Products: Distribution by Material Used for Fabrication
Table 21.27 Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
Table 21.28 Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
Table 21.29 Scaffold Free Product Developers: Distribution by Year of Establishment
Table 21.30 Scaffold Free Product Developers: Distribution by Company Size
Table 21.31 Scaffold Free Product Developers: Distribution by Location of Headquarters
Table 21.32 Leading Developers: Distribution by Number of Scaffold Free Products
Table 21.33 Tree Map Representation: Distribution by Type of Product and Company Size
Table 21.34 3D Bioreactors: Distribution by Type of 3D Bioreactor
Table 21.35 3D Bioreactors: Distribution by Working Volume
Table 21.36 3D Bioreactor Developers: Distribution by Year of Establishment
Table 21.37 3D Bioreactor Developers: Distribution by Company Size
Table 21.38 3D Bioreactor Developers: Distribution by Location of Headquarters
Table 21.39 Leading Developers: Distribution by Number of 3D Bioreactors
Table 21.40 3D Cell Culture Systems: Distribution by Key Application Areas
Table 21.41 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
Table 21.42 Scaffold Based Products: Distribution by Key Application Areas
Table 21.43 Scaffold Free Products: Distribution by Key Application Areas
Table 21.44 3D Bioreactors: Distribution by Key Application Areas
Table 21.45 Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015-Q3 2020
Table 21.46 Funding and Investments: Cumulative Number of Instances by Year, 2015–Q3 2020
Table 21.47 Funding and Investments: Cumulative Amount Invested, 2015–Q3 2020 (USD Million)
Table 21.48 Funding and Investments: Distribution of Instances by Type of Funding, 2015–Q3 2020
Table 21.49 Funding and Investments: Year-Wise Distribution by Number of Instances and Type of Funding, 2015 – Q3 2020
Table 21.50 Funding and Investments: Distribution of Amount Invested by Type of Funding, 2015 – Q3 2020 (USD Million)
Table 21.51 Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 – Q3 2020
Table 21.52 Funding and Investments: Distribution of Instances and Amount Invested by 3D Cell Culture Format, 2015–Q3 2020
Table 21.53 Funding and Investments: Distribution of Instances and Amount Invested by Type of Product, 2015–Q3 2020
Table 21.54 Funding and Investments: Distribution by Geography
Table 21.55 Funding and Investments: Regional Distribution by Total Amount Invested, 2015–Q3 2020
Table 21.56 Most Active Players: Distribution by Number of Funding Instances, 2015–Q3 2020
Table 21.57 Most Active Players: Distribution by Amount Raised, 2015–Q3 2020 (USD Million)
Table 21.58 Most Active Investors: Distribution by Funding Instances, 2015–Q3 2020
Table 21.59 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-Q3 2020
Table 21.60 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.61 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 21.62 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 21.63 Partnerships and Collaborations: Distribution by Type of Partner
Table 21.64 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 21.65 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 21.66 Partnerships and Collaborations: Distribution by 3D Cell Culture Format
Table 21.67 Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
Table 21.68 Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
Table 21.69 Partnerships and Collaborations: Distribution by Type of Product
Table 21.70 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Table 21.71 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 21.72 Most Active Players: Distribution by Number of Partnerships
Table 21.73 Partnerships and Collaborations: Regional Distribution
Table 21.74 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 21.75 Patent Analysis: Distribution by Type of Patent
Table 21.76 Patent Analysis: Cumulative Distribution by Publication Year, 2015-Q3 2020
Table 21.77 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-Q3 2020
Table 21.78 Patent Analysis: Distribution of Filed Patents Publication Year, 2015-Q3 2020
Table 21.79 Patent Analysis: Distribution by Number of Patent Type and Publication Year, 2015-Q3 2020
Table 21.80 Patent Analysis: Distribution by Issuing Authorities Involved
Table 21.81 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2015-Q3 2020
Table 21.82 Leading Patent Assignees (Industry Players): Distribution by Number of Patents
Table 21.83 Leading Patent Assignees (Non-Industry Players): Distribution by Number of Patents
Table 21.84 Patent Analysis: Distribution by Patent Age, 2000-2020
Table 21.85 Patent Analysis: Valuation Analysis
Table 21.86 Global 3D Cell Culture Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.87 Global 3D Cell Culture Market: Distribution by Business Segment, 2020 and 2030
Table 21.88 3D Cell Culture Systems Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.89 3D Cell Culture Consumables Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.90 3D Cell Culture Services Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.91 Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2020 and 2030
Table 21.92 3D Cell Culture Systems Market for Scaffold based Products, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.93 3D Cell Culture Systems Market for Scaffold Free Products, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.94 3D Cell Culture Systems Market for Market 3D Bioreactors, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.95 Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2020 and 2030
Table 21.96 3D Cell Culture Systems Market for Attachment Resistant Surfaces, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.97 3D Cell Culture Systems Market for Hydrogels / ECMs, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.98 3D Cell Culture Systems Market for Micropatterned Surface, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.99 3D Cell Culture Systems Market for Microcarriers, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.100 3D Cell Culture Systems Market for Microfluidic Systems, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.101 3D Cell Culture Systems Market for Solid Scaffolds, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.102 3D Cell Culture Systems Market for Suspension Culture Systems, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.103 Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2020 and 2030
Table 21.104 3D Cell Culture Systems Market for Cancer Research, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.105 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.106 3D Cell Culture Systems Market for Stem Cell Research, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.107 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.108 Global 3D Cell Culture Systems Market: Distribution by Purpose, 2020 and 2030
Table 21.109 3D Cell Culture Systems Market for Research Use, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.110 3D Cell Culture Systems Market for Therapeutic Use, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.111 Global 3D Cell Culture Systems Market: Distribution by Geography, 2020 and 2030
Table 21.112 3D Cell Culture Systems Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.113 3D Cell Culture Systems Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.114 3D Cell Culture Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.115 3D Cell Culture Systems Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.116 3D Cell Culture Systems Market in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.117 3D Cell Culture Systems Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.118 Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
Table 21.119 Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Table 21.120 Survey Insights: Distribution of Respondents by Year of Establishment of Company
Table 21.121 Survey Insights: Distribution of Respondents by Company Size
Table 21.122 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
Table 21.123 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Table 21.124 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Table 21.125 Survey Insights: Distribution by Focus Area
Table 21.126 Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
Table 21.127 Survey Insights: Distribution by Development Status of Product(s)
Table 21.128 Survey Insights: Distribution by Method of Fabrication Used
Table 21.129 Survey Insights: Distribution by Source of Cultured Cells
Table 21.130 Survey Insights: Distribution by Key Application Areas
Table 21.131 Survey Insights: Distribution by 3D Cell Culture Services Offered
Table 21.132 Survey Insights: Distribution by Current and Future Market Opportunity, 2020 and 2030

List Of Company

The following companies / organizations have been mentioned in this report.

  1. 101Bio
  2. 3D Biomatrix
  3. 3D Biotek
  4. 3D Biotechnology Solutions
  5. 3Dnamics
  6. 4Dcell
  7. 4titude
  8. AbbVie Ventures
  9. abc biopply
  10. ABL Europe
  11. Åbo Akademi University
  12. Abstraction Ventures
  13. Abzena
  14. Accellta
  15. Advanced BioMatrix
  16. Advanced Regenerative Manufacturing Institute (ARMI)
  17. Advanced Scientifics
  18. Aetos Biologics
  19. Afirmus Biosource
  20. AGC
  21. Agency for Science, Technology and Research (A*STAR)
  22. AIM Biotech
  23. Akero Therapeutics
  24. Akron Biotech
  25. Alector
  26. Allevi
  27. Alnylam Pharmaceuticals
  28. American Laboratory Products
  29. Alphabioregen
  30. ALS Investment Fund
  31. AlveoliX
  32. AMS Biotechnology 
  33. AnaPath Services
  34. Angel Investors
  35. AngelMD
  36. Angels 5K 
  37. Angels in MedCity
  38. Angels Santé
  39. Anthrogenesis
  40. Aquitaine Science Transfert
  41. Aquiti Gestion 
  42. AR Brown
  43. ARL Design
  44. ARTeSYN Biosolutions
  45. AstraZeneca
  46. Arizona State University
  47. ATEL Ventures
  48. Atera
  49. Avantor
  50. AxoSim
  51. AXT
  52. Axxicon 
  53. BASF
  54. Bayer
  55. B-CULTURE
  56. BEOnChip
  57. Bio-Byblos Biomedical 
  58. BioCat 
  59. BioConcept
  60. BIOFABICS
  61. Biogelx
  62. Bioinspired Solutions
  63. BioInvent International
  64. BIOKÉ
  65. BioLamina 
  66. Biomaterials USA
  67. Biomerix
  68. BiomimX
  69. Biopredic International
  70. BioTek Instruments
  71. BiSS TGT 
  72. Bonus BioGroup
  73. Bpifrance
  74. BRAIN
  75. BrainXell
  76. Brammer Bio
  77. Braveheart Investment Group
  78. Bristol-Myers Squibb
  79. Broad Institute
  80. BRTI Life Sciences
  81. Cambridge Bioscience
  82. University of Cambridge
  83. CarThera
  84. Cedars-Sinai Medical Center
  85. Celartia
  86. Cell Applications
  87. Cell Culture 
  88. CELLEC BIOTEK
  89. Cellendes
  90. Cellevate
  91. CELLnTEC
  92. CellSpring
  93. CellSystems
  94. CelVivo
  95. Center for the Advancement of Science in Space
  96. CESCO Bioengineering
  97. Charles River Laboratories
  98. Cherry Biotech
  99. China Regenerative Medicine International
  100. CITIC Securities
  101. CN Bio Innovations
  102. CN Innovations
  103. Collagen Solutions
  104. Comune di Milano
  105. Corning Life Sciences 
  106. Cosmo Bio
  107. CELLphenomics
  108. Commonwealth Serum Laboratories
  109.  Curi Bio
  110. Cyprio
  111. Cyprotex
  112. Cytiva
  113. Danaher
  114. Deepbridge Capital
  115. Demcon
  116. United States Department of Defense
  117. Development Bank of Wales
  118. DiPole Materials
  119. Downing Ventures
  120. Government of the Netherlands
  121. Executive Agency for Small and Medium-sized Enterprises (EASME)
  122. EBERS
  123. Ectica Technologies
  124. EDITHGEN
  125. Electrospinning
  126. Emulate
  127. Enso Discoveries
  128. Eppendorf
  129. Esco Aster
  130. Esperante
  131. Ethicon
  132. European Life Sciences Growth Fund (ELSGF)
  133. European Commission
  134. European Union
  135. Eurostars
  136. EU-ToxRisk
  137. Eva Scientific
  138. Evotec 
  139. faCellitate
  140. Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  141. Fennik Life Sciences
  142. Ferentis
  143. FHNW University
  144. FiberCell Systems
  145. Fibralign
  146. Finep
  147. Finesse Solutions
  148. Finovam Gestion
  149. Flexcell International
  150. Foundation for Technological Innovation
  151. Founder
  152. Founders Fund
  153. Freeline
  154. French Government
  155. Frequency Therapeutics
  156. FroggaBio
  157. Fujifilm
  158. FUJIFILM Wako Pure Chemical
  159. Funakoshi
  160. Gabriel Investments
  161. Galapagos 
  162. GALIA Gestion
  163. Gamma 3
  164. Gelmetix 
  165. Gelomics
  166. Gemini Bio
  167. Gemstone Biotherapeutics
  168. Genome Institute of Singapore
  169. Georgia Research Alliance 
  170. Global Cell Solutions
  171. Government of China
  172. Great Stuff Ventures
  173. GSI
  174. GlaxoSmithKline
  175. HµREL
  176. Hamilton 
  177. Harvard Apparatus
  178. Harvard College
  179. HCS Pharma
  180. Helvoet
  181. Heraeus Medical
  182. Hesperos
  183. Histogenics
  184. Human Models for Analysis of Pathways (HMAPs) Center
  185. Hokkaido Soda
  186. HP Wild Holding
  187. Hubrecht Organoid Technology 
  188. Humanetics
  189. Hyamedix
  190. ibidi
  191. IMSS-Gulf Bio Analytical
  192. INITIO CELL
  193. Innovate UK
  194. Innovation Fund Denmark
  195. Inova Health System 
  196. inRegen
  197. InSphero
  198. Invitrocue
  199. InvivoSciences
  200. Ionis Pharmaceuticals
  201. Irdi Soridec Gestion
  202. Janssen Biotech
  203. Japan Vilene Company
  204. Jellagen Marine Biotechnologies
  205. Johns Hopkins University
  206. JRI Orthopaedics 
  207. Kero
  208. Kim & Friends
  209. Kirkstall
  210. KIYATEC
  211. KOKEN
  212. Koninklijke Nederlandse Akademie Van Wetenschappen
  213. Kuraray
  214. LabCorp
  215. Laconia
  216. LAMBDA Laboratory Instruments
  217. Lantern Pharma
  218. Lawrence J. Ellison Institute for Transformative Medicine
  219. LBA Healthcare Management
  220. Lena Biosciences
  221. LFB Biomanufacturing
  222. Life Technologies 
  223. Lifecore Biomedical
  224. LifeNet Health
  225. Laboratory for Integrated Micro Mechatronic Systems
  226. Lineage Cell Therapeutics
  227. Locate Bio
  228. London School of Hygiene & Tropical Medicine
  229. Lonza
  230. Lund University
  231. LuoLabs
  232. Manchester BIOGEL
  233. University of Mannheim
  234. Maryland Momentum Fund
  235. Massachusetts Institute of Technology
  236. MassChallenge
  237. MatTek Life Sciences
  238. MBL International
  239. GlassWall Syndicate
  240. Menicon Life Science
  241. Merck Accelerator
  242. Merck Millipore
  243. Michael J. Fox Foundation
  244. Michigan Technological University
  245. Micronit
  246. MicroTissues
  247. Midven
  248. MIMETAS
  249. Minerva Business Angel Network
  250. Molecular Devices
  251. Maryland Stem Cell Research Fund (MSCRF)
  252. MTTlab
  253. Nanobiose
  254. Nano Dimension
  255. Nanofiber Solutions
  256. Nanogaia
  257. National Aeronautics and Space Administration
  258. National Center for Advancing Translational Sciences
  259. National Institute of Health
  260. National Institute on Aging
  261. National Institutes for Food and Drug Control 
  262. National Science Foundation
  263. National University Hospital
  264. National University of Singapore
  265. National Centre for the Replacement, Refinement and Reduction of Animals in Research
  266. Neuromics
  267. New Orleans BioFund
  268. Newable Private Investing
  269. Nexcelom Bioscience
  270. Nord France Amorquage
  271. Invest Northern Ireland
  272. Northwick Park Institute for Medical Research
  273. Nortis
  274. Nova Biomedical
  275. Novartis Venture Fund
  276. Noviocell
  277. Nucleus Biologics
  278. NYU Winthrop Hospital
  279. Olaregen Therapeutix
  280. OMNI Life Science
  281. Oregon Health & Science University
  282. Organovo
  283. Orthomimetics
  284. OS Fund
  285. Oxford MEStar
  286. Pairnomix
  287. Pall Corporation
  288. Path BioAnalytics
  289. PBS Biotech
  290. Peak Capital Advisors
  291. Pelo Biotech
  292. Pensees
  293. PepGel
  294. Percell Biolytica
  295. PerkinElmer
  296. Pfizer
  297. PHI 
  298. Pitch@Palace
  299. PL BioScience
  300. Plasticell 
  301. Pluristem Therapeutics
  302. Portugal Ventures
  303. Precision Biologics
  304. Premedical Laboratories
  305. Primorigen Biosciences
  306. Principia SGR
  307. ProBio
  308. ProBioGen
  309. Prodizen
  310. PromoCell
  311. Protista International
  312. QGel Bio
  313. QIAGEN (Suzhou) 
  314. Quintech Life Sciences
  315. PT Rajawali Medika Mandiri
  316. RASA
  317. React4life
  318. Real Research
  319. RealBio Technology
  320. Regemat3D
  321. Repligen
  322. REPROCELL
  323. Research Without Animal Experiment 
  324. Revivocell
  325. Rigenerand
  326. Roche
  327. RoosterBio
  328. Roswell Park Comprehensive Cancer Center
  329. Sanofi Ventures
  330. SARSTEDT
  331. Sartorius
  332. S-BIO
  333. ScienCell
  334. SciFi VC
  335. SciKon Innovation
  336. Scinus Cell Expansion
  337. Scottish Investment Bank 
  338. Seres Therapeutics
  339. Shanghai Cienle Medical Technology
  340. Shanghai Institute of Materia Medica
  341. Shanghai Institute of Biochemistry and Cell Biology
  342. Siemens Technology
  343. Sigma-Aldrich
  344. SKE Research Equipment
  345. SmiLe Incubator
  346. SoloHill Engineering
  347. Spheritech
  348. Spiber Technologies
  349. Start-Up Chile
  350. State Key Laboratory of Experimental Hematology
  351. StemCell Systems
  352. STEMCELL Technologies
  353. Stemmatters
  354. StemoniX
  355. StemTek Therapeutics
  356. SUN bioscience
  357. Commission for Technology and Innovation
  358. Swiss Federal Laboratories for Materials Science and Technology
  359. SyndicateRoom
  360. Synthecon
  361. SynVivo
  362. TA Instruments
  363. Takeda
  364. Tantti Laboratory
  365. tebu-bio
  366. TEDCO
  367. Terumo
  368. Texas Tech University Health Sciences Center 
  369. Development Bank of Wales
  370. Ministry of Higher Education, Research and Innovation (France)
  371. The Idea Village
  372. Institute for Molecular Medicine Finland
  373. Mario Negri Institute for Pharmacological Research
  374. University of Alberta
  375. University of Bath
  376. University of Brescia
  377. University of Bristol 
  378. University of Manchester
  379. University of Milan
  380. University of Strathclyde
  381. University of Zurich 
  382. TheWell Bioscience
  383. Thermo Fisher Scientific
  384. Tianjin Weikai Biological Engineering
  385. Tissue Click
  386. TissueLabs
  387. TissUse
  388. Tokyo Future Style
  389. TPG
  390. TreeFrog Therapeutics
  391. Trevigen
  392. Triumvirate Environmental
  393. Technical University of Berlin
  394. Twinhelix
  395. UK Innovation & Science Seed Fund
  396. Science and Technology Facilities Council (STFC)
  397. UK Science and Technology Facilities Council
  398. University of Genoa
  399. University College London
  400. University Hospital Zurich 
  401. Stanford University
  402. University of Arkansas for Medical Sciences
  403. University of California
  404. University of Central Florida
  405. University of Nottingham 
  406. The University of Sheffield
  407. University of Washington School of Pharmacy 
  408. University of Zurich 
  409. UPM Biomedicals
  410. U.S. Small Business Administration
  411. UW Medicine
  412. VA Portland Health Care System
  413. Vanderbilt University
  414. Venture Kick
  415. VentureSouth
  416. Venturecraft
  417. Viscofan BioEngineering
  418. Visikol
  419. Vivo Biosciences
  420. VWR
  421. Wake Forest Institute for Regenerative Medicine
  422. Women Who Tech
  423. XAnge
  424. Xenos
  425. XP Biomed
  426. Xylyx Bio
  427. Zhejiang University
  428. zPREDICTA

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com